Biotech update highlighting a Parkinson's research program and how it fits into the company's ambitious aging-focused R&D strategy.
Key Takeaways
- GBA1 mutations occur in roughly 5–15% of Parkinson's patients with earlier onset reported
- Michael J Fox Foundation funded a two-year grant for a GBA1-focused Parkinson's program
- Harness's approach targets glucocerebrosidase protein levels and intracellular delivery mechanisms